A PHASE I STUDY OF THE CEACAM5 x CD47 ANTIBODY NILK-2401 AS SINGLE AGENT OR IN COMBINATION WITH ANTI-PD-1 ANTIBODY IN SOLID CANCERS

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512175-12-00

Acronym

LCB-2401-001

Enrollment

Registered

2024-06-11

Start date

2024-11-14

Completion date

Unknown

Last updated

2025-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

also known as CEA)., Low tumour volume (LTV) advanced, metastatic, or recurrent solid malignancies expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

Spain

Outcome results